BenchSci has welcomed three new members to its advisory board from the pharmacology sector. Steve Hitchcock of Takeda Pharmaceuticals, Philip Tagari of Amgen, and Philip Just Larsen of Bayer join previous technologists Milind Kamkolkar (Cellarity) and Richard Zemel (University of Toronto) to oversee the AI platform’s growth and future goals.
BenchSci empowers scientists with the world’s most advanced biomedical AI to advance assets with fewer, more successful experiments. The company’s vision is to bring medicine to patients 50% faster by 2025.
The trio of Hitchcock, Tagari and Larsen have collective experience working across a variety of biotechnology and life sciences sectors including neuroscience, oncology, gastrointestinal diseases, rare diseases, novel molecules, diabetes and obesity.
BenchSci’s CEO, Liran Belenzon, highlighted the fact that the new board make-up will bring to the machine-learning platform, alongside leadership and global industry experience, “a deep understanding of the challenges facing life-science research that our platform is addressing.”
New addition Steve Hitchcock welcomed the opportunity saying: “I’m delighted to be able to work with the outstanding team at BenchSci who are broadly applying cutting-edge AI technologies to accelerate the discovery of new therapeutics.” Former Bayer Executive Philip Larsen echoed this view as well as indicating the challenges ahead, “The frontier of innovation for the life-science industry is defined by those who can bring sense to the overwhelming amount of data points generated every day.”
BenchSci delivers the world’s most advanced biomedical artificial intelligence allowing scientists to run more successful experiments without error. Advanced biomedical artificial intelligence helps researchers to run fewer but more successful experiments. The platform currently accelerates science at 75% of the world’s top pharmaceutical companies and over 4,000 leading research centers globally.